Skandinaviska Enskilda Banken Ab (Publ) Vertex Pharmaceuticals Inc Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

$20.3 Billion
Q1 2024

A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 264,923 shares of VRTX stock, worth $124 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares

264,923

Previous 243,738 8.69%

Holding current value

$124 Million

Previous $99.2 Million 11.66%

% of portfolio

0.54%

Previous 0.58%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$407.69 - $446.08 $8.64 Million - $9.45 Million	21,185 Added 8.69%	264,923 $111 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $28.4 Million - $34 Million	-82,892 Reduced 25.38%	243,738 $99.2 Million
Q3 2023 Nov 09, 2023	SELL	$338.18 - $362.46 $17 Million - $18.2 Million	-50,316 Reduced 13.35%	326,630 $114 Million
Q2 2023 Aug 07, 2023	SELL	$314.42 - $351.91 $21.1 Million - $23.6 Million	-67,057 Reduced 15.1%	376,946 $133 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $10.6 Million - $12.1 Million	37,469 Added 9.22%	444,003 $140 Million

Q4 2022 Feb 08, 2023	BUY	$285.76 - $321.48 $15.7 Million - $17.6 Million	54,823 Added 15.59%	406,534 $117 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $27 Million - $30.1 Million	98,458 Added 38.88%	351,711 $102 Million
Q2 2022 Aug 10, 2022	BUY	$234.96 - $292.55 $4.99 Million - $6.21 Million	21,221 Added 9.15%	253,253 $71.4 Million
Q1 2022 May 11, 2022	SELL	$221.42 - $260.97 $12.4 Million - $14.6 Million	-55,892 Reduced 19.41%	232,032 $60.6 Million
Q4 2021 Feb 10, 2022	SELL	$177.01 - $223.45 $1.8 Million - $2.27 Million	-10,161 Reduced 3.41%	287,924 $64 Million
Q3 2021 Nov 10, 2021	SELL	$181.39 - $202.99 $1.54 Million - $1.72 Million	-8,478 Reduced 2.77%	298,085 $54.1 Million
Q2 2021 Aug 10, 2021	SELL	$187.49 - $221.1 $7.25 Million - $8.54 Million	-38,644 Reduced 11.19%	306,563 $61.8 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $16.3 Million - $19 Million	78,854 Added 29.61%	345,207 $74.2 Million
Q4 2020 Feb 11, 2021	SELL	$207.01 - $276.09 $481,505 - $642,185	-2,326 Reduced 0.87%	266,353 $63 Million
Q3 2020 Nov 12, 2020	SELL	$255.65 - $303.1 $2.51 Million - $2.97 Million	-9,801 Reduced 3.52%	268,679 $73.1 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $23.8 Million - $31.2 Million	105,390 Added 60.89%	278,480 $80.8 Million
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $11.5 Million - $14.3 Million	57,812 Added 50.15%	173,090 $41.2 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $592,820 - $796,223	3,556 Added 3.18%	115,278 $25.2 Million
Q3 2019 Nov 08, 2019	BUY	$166.23 - $187.09 $2.24 Million - $2.52 Million	13,493 Added 13.74%	111,722 $18.9 Million
Q2 2019 Aug 09, 2019	SELL	$164.61 - $190.37 $1.34 Million - $1.55 Million	-8,136 Reduced 7.65%	98,229 $18 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $3.9 Million - $4.64 Million	23,809 Added 28.84%	106,365 $19.6 Million
Q4 2018 Feb 12, 2019	BUY	$151.91 - $192.21 $405,751 - $513,392	2,671 Added 3.34%	82,556 $13.7 Million
Q3 2018 Nov 05, 2018	BUY	$167.73 - $192.74 $201,276 - $231,288	1,200 Added 1.53%	79,885 $15.4 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $1.53 Million - $1.78 Million	10,485 Added 15.37%	78,685 $13.4 Million
Q1 2018 Apr 30, 2018	SELL	$151.6 - $177.13 $1.57 Million - $1.83 Million	-10,331 Reduced 13.16%	68,200 $11.1 Million
Q4 2017 Feb 12, 2018	SELL	$137.28 - $155.55 $2.14 Million - $2.43 Million	-15,600 Reduced 16.57%	78,531 $11.8 Million
Q3 2017 Nov 13, 2017	SELL	$148.13 - $162.24 $1.96 Million - $2.14 Million	-13,200 Reduced 12.3%	94,131 $14.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	107,331	107,331 $0

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.

Account

Skandinaviska Enskilda Banken Ab (Publ) Vertex Pharmaceuticals Inc Transaction History